T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and
poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate …

Mature T-cell lymphomas are aggressive malignancies. Treatment outcome is poor with
conventional chemotherapy. They are about twice as common in Asia as compared with …

Epigenetic modifications in eukaryotic biological pathways can lead to the up-or
downregulation of regulatory proteins contributing to disease onset and progression. In the …

Epigenetic modifications play central roles in cellular differentiation and their deregulations
really contribute to tumor development. Histone deacetylase (HDAC) enzymes can exert …

Although surgery is an important treatment for laryngeal cancer, surgery has a significant
negative impact on the quality of life of patients, and many patients have poor tolerance to …

Leukemia stem cells (LSCs) are responsible for treatment failure and relapse in acute
myeloid leukemia (AML). Therefore, development of novel LSCs-targeting therapeutic …

Intravesical instillation (IVI) of Bacillus Calmette-Guerin (BCG) can prevent bladder cancer
recurrence, but this agent has been out of stock in recent years. IVI of other agents, like …

Chidamide, a novel histone deacetylase (HDAC) inhibitor, induces antitumor effects in
various types of cancer. The present study aimed to evaluate the cytotoxic effect of …

Chidamide is a newly designed histone deacetylase (HDAC) inhibitor that has been applied
in clinical trials. This study aimed to test the effect of Chidamide on proliferation and …

Combination of low doses of histone deacetylases inhibitors and chemotherapy drugs is
considered as one of the most promising strategies to increase the anticancer efficacy …